Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company product TLANDO is an oral testosterone replacement therapy TRT. It also has other produ... Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company product TLANDO is an oral testosterone replacement therapy TRT. It also has other products in the pipeline such as LPCN 1144 LPCN 1148 and LPCN 1107. 詳細を表示
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis PR Newswire SALT LAKE CITY, Dec. 17, 2024 SALT LAKE CITY, Dec...
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session PR Newswire SALT LAKE CITY, Nov. 18, 2024 SALT LAKE CITY, Nov. 18, 2024...
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 PR Newswire SALT LAKE CITY, Nov. 7, 2024 SALT LAKE CITY, Nov. 7, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ:...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.05 | 1.0395010395 | 4.81 | 5.2151 | 4.5 | 37008 | 4.74234003 | CS |
4 | -0.1302 | -2.60911386317 | 4.9902 | 5.4699 | 4.5 | 32969 | 4.93849871 | CS |
12 | -0.34 | -6.53846153846 | 5.2 | 6.1683 | 4.01 | 28811 | 5.11101426 | CS |
26 | -2.95 | -37.7720870679 | 7.81 | 8.2266 | 3.5 | 30750 | 5.05980891 | CS |
52 | 2.1 | 76.0869565217 | 2.76 | 11.79 | 2.76 | 44163 | 5.73900037 | CS |
156 | -12.31 | -71.6948165405 | 17.17 | 32.13 | 2.3101 | 191096 | 14.50317155 | CS |
260 | -1.77 | -26.6968325792 | 6.63 | 41.14 | 2.3101 | 946947 | 23.56371104 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約